OmniActive Health Technologies is presenting a poster on the study “Soluble Lutein Inhibits Cholinesterase and Reduces Ultraviolet Radiation-Induced Inflammation and Immunosuppression: In vitro Model” at The Macular Carotenoids Conference’s (MCC) annual meeting, taking place from Wednesday, July 8 – Friday, July 10 at Downing College, Cambridge University (UK). The study was conducted by Vijaya Juturu PhD, F.A.C.N., manager of global scientific and clinical affairs, Khadija Ghanam, PhD, clinical nutritional biochemist, and Jayant Deshpande, PhD, CTO—all of OmniActive Health Technologies.
 
This in vitro study evaluated the effect of the macular carotenoids— lutein and the two zeaxanthin isomers (Lutemax 2020)— on cholinesterase activity and antioxidant enzymes in response to ultraviolet (UV) irradiation. Lutein and zeaxanthin isomers may ameliorate the effects of mild UV irradiation on Retinal Pigment Epitheleal (RPE) cells, as shown by expression of genes involved in cell proliferation, inflammation, immune function and wound healing. Lutein and zeaxanthin isomers inhibited cholinesterase activity and enhanced catalase activity in cells exposed to mild irradiation. These results suggest inhibition of cholinesterase enzyme and enhancing antioxidant enzymes may have several therapeutic applications such as neurodegenerative disorders and myasthenia gravis.  
 
“We are excited to see from this Lutemax 2020 study these new insights into the critical role that lutein and zeaxanthin isomers (RR-zeaxanthin and RS (meso)-zeaxanthin) may play in eye health, specifically as potent antioxidants and anti-inflammatory agents protecting retinal tissue,” stated Jayant Desphande, chief technology officer, OmniActive Health Technologies.
 
The study Soluble Lutein Inhibits Cholinesterase and Reduces Ultraviolet Radiation-Induced Inflammation and Immunosuppression: In vitro Model is a product of the OmniActive’s robust scientific program as well as another significant addition to the growing science on the macular carotenoids.
 
For more information: omniactives.com